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Cellular/Molecular
Adenosine A1 Receptor Protects Against Cisplatin
Ototoxicity by Suppressing the NOX3/STAT1 Inflammatory
Pathway in the Cochlea
Tejbeer Kaur,1* XVikrant Borse,2* Sandeep Sheth,2 XKelly Sheehan,3 Sumana Ghosh,2 Srinivasan Tupal,2
Sarvesh Jajoo,2 XDebashree Mukherjea,3 XLeonard P. Rybak,2,3 and Vickram Ramkumar2
1Department of Otolaryngology, Washington University School of Medicine, St. Louis, Missouri 63110, and 2Department of Pharmacology and 3Department
of Surgery, Southern Illinois University School of Medicine, Springfield, Illinois 62794
Cisplatin is a commonly used antineoplastic agent that produces ototoxicity that is mediated in part by increasing levels of reactive
oxygen species (ROS) via the NOX3 NADPH oxidase pathway in the cochlea. Recent studies implicate ROS generation in mediating
inflammatory and apoptotic processes and hearing loss by activating signal transducer and activator of transcription (STAT1). In this
study, we show that the adenosine A1 receptor (A1AR) protects against cisplatin ototoxicity by suppressing an inflammatory response
initiated by ROS generation via NOX3 NADPH oxidase, leading to inhibition of STAT1. Trans-tympanic administration of the A1AR
agonistR-phenylisopropyladenosine (R-PIA) inhibited cisplatin-induced ototoxicity, asmeasured by auditory brainstem responses and
scanning electronmicroscopy inmaleWistar rats. This was associatedwith reducedNOX3 expression, STAT1 activation, tumor necrosis
factor- (TNF-) levels, and apoptosis in the cochlea. In vitro studies in UB/OC-1 cells, an organ of Corti immortalized cell line, showed
thatR-PIA reduced cisplatin-inducedphosphorylation of STAT1 Ser727 (but not Tyr701) and STAT1 luciferase activity by suppressing the
ERK1/2, p38, and JNKmitogen-activated protein kinase (MAPK) pathways. R-PIA also decreased the expression of STAT1 target genes,
such as TNF-, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and reduced cisplatin-mediated apoptosis. These
data suggest that the A1AR provides otoprotection by suppressing NOX3 and inflammation in the cochlea and could serve as an ideal
target for otoprotective drug therapy.
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Introduction
Adenosine is a ubiquitous metabolite of ATP, which mediates its
physiological actions in part by activating adenosine A1 receptors
(A1ARs). These receptors have been extensively characterized for
their role in cytoprotection. Activation of the A1AR protects
against ischemic and oxidative stress in the cardiovascular sys-
tem, renal system, andCNS. Several effector systems regulated by
the A1AR, such as adenylyl cyclase, K
 channels, and antioxidant
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Significance Statement
Cisplatin is a widely used chemotherapeutic agent for the treatment of solid tumors. Its use results in significant and permanent
hearing loss, for which noUS Food andDrugAdministration-approved treatment is currently available. In this study, we targeted
the cochlear adenosine A1 receptor (A1AR) by trans-tympanic injections of the agonistR-phenylisopropyladenosine (R-PIA) and
showed that it reduced cisplatin-induced inflammation and apoptosis in the rat cochlea andpreservedhearing. Themechanismof
protection involves suppression of theNOX3NADPHoxidase enzyme, amajor target of cisplatin-induced reactive oxygen species
(ROS) generation in the cochlea. ROS initiates an inflammatory and apoptotic cascade in the cochlea by activating STAT1 tran-
scription factor, which is attenuated byR-PIA. Therefore, trans-tympanic delivery of A1AR agonists could effectively treat cispla-
tin ototoxicity.
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enzymes, likely contribute to cytoprotection (Fredholm et al.,
2011). A cytoprotective role of adenosine has been clearly defined
in the CNS. For example, adenosine protects against transient
ischemia (Daval et al., 1989; Rudolphi et al., 1992) and against
audiogenic seizures (De Sarro et al., 1991). Activation of the
A1AR plays an important role in limiting seizures and the subse-
quent neuronal cell death resulting from them (Boison, 2006).
Accordingly, a lack of A1AR predisposes mice to seizure-induced
deaths (Fedele et al., 2006; Kochanek et al., 2006). In contrast,
induction of A1AR expression in the rat brain by chronic caffeine
ingestion renders these animals more resistant to cerebral isch-
emia (Rudolphi et al., 1989), whereas downregulation of these
receptors exacerbated the ischemic damage (von Lubitz et al.,
1994). Adenosine is also an important mediator of ischemic pre-
conditioning, a process by which prior ischemic challenges con-
fer resistance to subsequent ischemic damage (Schulte et al.,
2004; Lankford et al., 2006).
A role of adenosine in cochlear functions was suggested from
early experiments in the frog labyrinth system, a model system for
studying hair cell function. These experiments indicate modulation
of afferent neurotransmission in hair cells by adenosine (Bryant et
al., 1987). Studies fromour laboratory (Ramkumar et al., 1994)were
the first to provide direct evidence of cochlear A1AR in rat. At ap-
proximately the same time, Nario et al. (1994) demonstrated that
perilymphatic perfusion of adenosine decreased endocochlear po-
tentials in the guinea pig.Wehave also shown that administrationof
the A1AR agonist R-phenylisopropyladenosine (R-PIA) to rats via
round window application increased the activities of antioxidant
enzymes and reduced lipid peroxidation in the cochlea in vivo (Ford
et al., 1997), supporting a protective role of the cochlear A1AR. R-
PIA was also shown to protect cochlear explants from damage in-
ducedby cisplatin (Huet al., 1997) and against noise-induced loss of
hair cells in the rat cochlea (Hight et al., 2003).
More recent studies have confirmed the protective role of
adenosine and the A1AR in cochlear protection. For example, the
adenosine amine congener (ADAC) protected against noise-
induced hearing loss when administered by the intraperitoneal
route (Vlajkovic et al., 2010). A combination of R-PIA and glu-
tathione monoethylester protects against noise-induced hearing
loss in the chinchilla cochlea. Furthermore, elevation of adeno-
sine levels by inhibition of adenosine kinase protected against
age-related hearing loss (Vlajkovic et al., 2011) and ADAC pro-
tected against cisplatin ototoxicity (Gunewardene et al., 2013).
A role of inflammation in sensorineural hearing loss is sup-
ported by several observations. For example,middle ear infection
(otitis media; Paparella et al., 1972) and meningitis (Merchant
and Gopen, 1996) are usually associated with hearing loss in chil-
dren. Noise trauma could also induce an inflammatory response
in the inner ear (Fujioka et al., 2006). A recent study has shown
that cisplatin-induced ROS generation is a key contributor to
cochlear inflammation and apoptosis of cells in the cochlea (Kaur
et al., 2011). In this study, we show that ROS activation of signal
transducer and activator of transcription 1 (STAT1) contributes
to cisplatin-induced inflammation and ototoxicity. Moreover,
we show that the A1AR-mediated protection involves suppres-
sion of ROS-dependent inflammatory response in the cochlea.
Materials andMethods
Drugs and reagents. Cisplatin (-)-N6-(2-Phenylisopropyl)-adenosine
(R-PIA), 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX), diphenylenei-
odonium (DPI), and TRI reagent, ERK1/2 inhibitor (PD98059) were
purchased from Sigma-Aldrich. 2,7-dichlorodihydrofluorescein diace-
tate (H2DCFDA) dye for ROS generation was from EMD Biosciences.
JNK inhibitor (SP600125) was from Tocris Bioscience and p38 inhibitor
(SB230580) was from Calbiochem. Various antibodies used and their
dilutions were as follows: STAT1 (1:5000), inducible nitric oxide syn-
thase (iNOS, 1:1000), cyclooxygenase-2 (COX-2, 1:1000), tumor necro-
sis factor- (TNF-, 1:500), p-STAT1 (1:1000) (both serine 727 and
tyrosine 701), caspase-3 (1:1000), Bcl2 (1:1000), Phospho p38 and p38
(1:1000) ( all fromCell Signaling Technology). Rabbit polyclonalmyosin
VIIA antibody (1:200) was from Proteus Biosciences (catalog #25-6790).
Phospho ERK1/2 (1:2000) and ERK1/2 (1:4000), A1AR (1:100), goat
anti-rabbit, donkey anti-goat, and goat anti-mouse secondary antibodies
were from Santa Cruz Biotechnology. Fluorescent-tagged (Dylight 488
and TRITC) secondary antibodies were from Jackson ImmunoResearch.
Animal procedures and sample collection.MaleWistar rats (200–250 g)
were used for this study. Pretreatment auditory brainstem responses
(ABRs) were performed immediately before trans-tympanic application
of R-PIA or DPCPX R-PIA for 1 h. Cisplatin (11 mg/kg) was admin-
istered intraperitoneally over a period of 30 min using an infusion pump
in rats anesthetizedwith ketamine and xylazine. Therewas no evidence of
middle ear effusion or infection in these animals. Posttreatment ABRs
were then performed 72 h after cisplatin administration. Cochleae were
dissected and used for total RNA and perfused with 2.5% glutaraldehyde
for scanning electron microscopy (SEM) or with 4% paraformaldehyde
for immunohistochemistry. All animal procedures used were approved
by the Southern Illinois University Laboratory Animal Care and Use
Committee.
Trans-tympanic administration of adenosine A1 receptor agonist and
antagonist. The procedure used for trans-tympanic administration of
adenosine A1 receptor agonist and antagonist was similar to that used in
our laboratory in rats previously (Mukherjea et al., 2010). Rats were
anesthetized with ketamine and xylazine. Fifty microliters of solution
were injected into the middle ear (drugs were resuspended in 50 l
solution, pH 7.2, for the desired concentration). The rat was then left
undisturbed for 15 min with the treated ear facing up. This procedure
was then repeated in the other ear.
Evoked potentials. ABRs were determined as described previously
(Mukherjea et al., 2008). Animals were tested with a stimulus intensity
series that was initiated at 10 dB SPL and reached a maximum at 90 dB
SPL, with 10 dB increments. The auditory stimuli included tone bursts at
8, 16, and 32 kHz with a 5 ms plateau and a 1 ms rise/fall time presented
at a rate of 5 /s. Threshold was defined as the lowest intensity capable of
evoking a reproducible, visually detectable response with two distinct
waveforms (from waves 2 and 3) and minimum amplitude of 0.5 V.
These waves were chosen because they consistently showed the highest
amplitudes and were more responsive to lower sound levels.
Morphological studies by SEM. Immediately after completion of post-
treatment ABRs, deeply sedated rats were killed and their cochleae were
harvested and processed as described previously (Mukherjea et al., 2008).
Sputter-coated cochleae were then viewed and photographed with a Hi-
tachi S-500 scanning electron microscope.
Hair cell count. Hair cell counts were performed as described previ-
ously (Mukherjea et al., 2008). Two representative areas of the basal turn,
middle turn, and apex and hook portion were photographed. In each
area, outer hair cells (OHCs) were counted in an area that was 10 pillar
cell heads in length. The results are presented as the percentage hair cell
damage per cochlear turn. At least three cochleae from different animals
per treatment group were used.
Processing of cochleae for immunohistochemistry. Cochleae were per-
fused with 4% paraformaldehyde, decalcified in 0.1 M EDTA, pH 7.4, at
room temperature for 2 weeks, paraffin embedded, and sectioned. Im-
munolabeling studies were performed as described previously (Mukher-
jea et al., 2008, 2011). Slides were then imaged using a Leica confocal
microscope. Images were analyzed and quantified using the Leica confo-
cal microscope software (LAS AF Lite). From each sample, immunoflu-
orescence readings were captured from five different regions of the stria
vascularis and spiral ligament or individual cells (for the spiral ganglion
and hair cells). Ten cells were counted for each sample in the spiral
ganglion and threeOHCswere counted in organ of Corti. Care was taken
to choose sections from approximately the same area (basal turn) of the
cochlea. The readings were averaged to give the final fluorescence for
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each cochlear region. Other decalcified samples were used for whole-
mount preparations, which were used to show expression of A1AR and
myosin VIIA in the inner hair cells (IHCs) and OHCs.
TUNEL assay in cochlear sections. In vivo apoptosis was detected by
TUNEL assay using Fluorescein FragELTM DNA fragmentation detec-
tion kit (EMD Biosciences). Briefly, cochleae were perfused with 4%
paraformaldehyde, decalcified for 2 weeks, paraffin embedded, and sec-
tioned. The cochlear sections were then deparaffinized and rehydrated,
followed by permeabilization of the sections using proteinase K (1:100
dilution) (provided in the kit) for 20 min at room temperature. At the
end of incubation, the slides were rinsed with 1 Tris-buffered saline
(TBS). The slides were then incubated with 1 terminal deoxynucleoti-
dyl transferase (TdT) equilibration buffer for 10–30min. After the incu-
bation was over, 60 l of TdT labeling reaction mixture was applied on
each section and the slides were the placed in a humidified chamber and
incubated for 1–1.5 h at 37°C. Next, the slides were rinsed twice with 1
TBS. Glass coverslips were mounted using Fluorescein-FragELTM
mounting medium. Excess mounting media was wiped off and the edges
were sealed using nail polish. Slides were then imaged using a Leica
confocal microscope.
Cell culture. Immortalized organ ofCorti cells derived from themouse,
UB/OC-1 cells, were obtained from Dr. Matthew Holley (Institute of
Molecular Physiology, Sheffield, UK) and cultured in RPMI 1640 sup-
plemented with 10% Fetalclone II serum (Hyclone), penicillin/strepto-
mycin, and normocin (Invitrogen). Cultures were grown at 33°C in an
incubator with 10% CO2.
H2DCFDA assay. ROS generation was measured with the green fluo-
rescent dye H2DCFDA as described previously (Mukherjea et al., 2008).
Briefly, UB/OC-1 cells were treated with DPCPX (3 M) for a half hour,
followed by R-PIA (1 M) for another half hour. Cells were then treated
with cisplatin for 15 min, followed by incubation with 5 M H2DCFDA
dye for 15 min. ROS generation was detected as green fluorescence by
confocal microscopy.
Immunocytochemistry. To detect nuclear translocation of p-STAT1 af-
ter cisplatin treatment by immunofluorescence staining, UB/OC-1 cells
were first plated in a 12 well plate. After the cells adhered to the plate
surface, theywere treatedwith 3MDPCPX for a half hour and thenwith
R-PIA (1M) for another half hour. At the end of incubation period, cells
were treated with cisplatin (2.5 M) for 45 min. After the treatment, the
cells were fixedwith 4%paraformaldehyde (Sigma-Aldrich), followed by
washing with 1 PBS. Coverslips were then incubated with solution A, a
mixture of 5% donkey serum (Jackson ImmunoResearch) and 0.5%
Triton-X (Sigma-Aldrich) in PBS for 30 min at room temperature. Pri-
mary antibody against p-STAT1 (1:300 dilution) in solution A was then
added and incubated at 4°C overnight. After 3 washes with 1 PBS, the
cells were incubated with Dylight 488-labeled anti-rabbit secondary an-
tibody (1:600 dilution) in the dark for 1 h. After 3 washes with 1 PBS
and 2 washes with fresh distilled water, the coverslips were mounted on
glass slides using Vectashield mounting medium (Vector Laboratories)
before examination under a Leica confocal microscope.
Apoptosis detection by flow cytometry. Apoptotic cells were labeled
and visualized using an FITC Annexin V Apoptosis detection kit (BD
PharMingen). Briefly, UB/OC-1 cells were treated with DPCPX (3 M)
for a half hour, followed by R-PIA (1 M) for another half hour. Cells
were then treated with cisplatin (20 M) for another 24 h. At the end of
the treatment, the cells were washed with PBS and harvested in a 0.5%
trypsin/EDTA solution at 37°C, centrifuged at 220  g for 5 min, and
then immediately resuspended in the buffer provided in the kit. Cells
(1  105 cells/500 l) were then maintained in the dark for 15 min at
room temperature with 5l of both FITC-conjugated Alexa Fluor V and
propidium iodide and samples were analyzed immediately by a flow
cytometry (BD FACSCalibur). The results were analyzed using the Cell-
Quest software provided with the FACSCalibur. Early apoptotic cells are
displayed in the lower right quadrant of each dot plot; necrotic or late
apoptotic cells are reported in the upper right quadrant of the plot.
Flow cytometry for A1AR expression. UB/OC-1 cells were treated with
either vehicle or cisplatin (2.5 M) for 24 h. At the end of the 24 h
incubation period, the cells were resuspended in 1 PBS 10% fetal calf
serum  1% sodium azide solution, followed by staining with the un-
conjugated primary antibody solution of goat polyclonal A1AR IgG (cat-
alog #sc-7500; Santa Cruz Biotechnology) at a 1:200 dilution in 3% BSA
in 1PBS at 4°C for 30 min. After washing the pellet twice with 1 PBS,
the cells were stained with secondary antibody solution (FITC goat anti-
rabbit; 1:100 in 3%BSA in 1 PBS) for 30min in the dark at 4°C. Finally,
the pellet was resuspended in 1 PBS  3% BSA  1% sodium az-
ide solution and labeled cells were analyzed by flow cytometry (BD
FACSCalibur). The results were analyzed using the Cell Quest software
provided with the FACSCalibur.
Luciferase assay.UB/OC-1 cells were transfected with 0.8g of STAT1
p84/91 from Panomics and 0.2 g of pGL3 Renilla, a kind gift from Dr.
Y.Y Mo (University of Mississippi Medical Center, Jackson, MS) using
SuperFect transfection reagent (Qiagen). Briefly, for eachwell of a 12well
plate, plasmidDNAmixed in 75l of serum-freemedia, 0.8g of STAT1
luciferase plasmid, and 0.2 g of pGL3 Renilla luciferase plasmid was
diluted, mixed, and incubated for 5 min. Transfection reagent (6l) was
added to the above solution, vortexed gently, and incubated for 10min at
room temperature. The DNA transfection reagent complex was then
added to the wells containing 400l of serum-free medium. The serum-
free medium was changed with whole serum medium after 6 h and the
plate was incubated for another 30 h at 33°C. Pretreatments withDPCPX
(3 M) and R-PIA (1 M) were performed for 30 min, followed by treat-
ment with cisplatin (2.5 M) for another 8 h. Luciferase activity was
assessed with the Dual-Luciferase Reporter Assay kit (Promega) accord-
ing to themanufacturer’s protocol. Briefly, the cells were harvested using
the lysis buffer provided in the kit. Next, 25 l of the lysate was mixed
with 25 l of luciferase assay substrate and luciferase activity was mea-
sured using a Berthold detection system luminometer. To measure the
activity of the control Renilla luciferase, 25 l of Stop & Glo substrate
(Promega) was then added to the lysate mixture and luminescence was
measured again. Renilla luciferase was used for normalization.
Western blot analysis.UB/OC-1 cells were homogenized in ice-cold 50
mM Tris HCl, 10mMMgCl2, and 1mM EDTA in the presence of protease
inhibitor mixture (Sigma-Aldrich) and phosphatase inhibitor 1 (Sigma-
Aldrich). The whole-cell lysates were then used for Western blotting as
described previously (Jajoo et al., 2009). After transfer to nitrocellulose
membranes, blots were probed with different primary antibodies, fol-
lowed by a horseradish peroxidase-tagged secondary antibody, and visu-
alized by chemiluminescence detection (Pierce Biotechnology) using
charged-coupled device LAS 4000 (Fujifilm). Densitometric analysis of
the blots was performed with MultiGauge version 2.0 software.
RNA isolation and real timeRT-PCR.RNAwas isolated fromUB/OC-1
cell cultures and rat cochleae by adding 1 ml of TRI reagent to 100 mg of
each cochlea or 0.5 ml of TRI reagent per well of each 6 well plate and
real-time RT-PCR studies were also performed as described previously
(Mukherjea et al., 2008, 2011). The cycle number at which the sample
reaches the threshold fluorescent intensity was termed the cycle thresh-
old (Ct). The relative change in mRNA levels between untreated control
(1) and treated sample (2) was measured using the following formula:
2 (Ct Target gene1Ct GAPDH1)(Ct Target gene2Ct GAPDH2) (Soong et al.,
2001). Negative controls for both target gene and GAPDHwere used for
all reaction groups. Gene-specific primer pairs were used for the various
reactions and mRNA expression levels were normalized to the levels of




(sense): 5-GTGAACAAGGGAAGGCTCAT-3; (antisense): 5-GACCCA
CAGAAGAACACGC-3; rodent-STAT1 (sense): 5-CATGGAAATCAGA
CAGTACCT-3; (antisense): 5-TCTGTACGGGATCTTCTTGGA-3; ro-
dent-TNF- (sense): 5-CAGACCCTCACACTCAGATCA-3; (antisense):
5-TGAAGAGAACCTGGGAGTAGA-3; rodent-iNOS (sense):5-
CATTCTACTACTACCAGATC-3; (antisense): 5-ATGTGCTTGTCAC
CACCAG-3; rodent-COX-2 (sense): 5-TGATCGAAGACTACGT
GCAAC-3; (antisense): 5-GTACTCCTGGTCTTCAATGTT-3; rodent-
A1AR (sense): 5-CATCCCACTGGCCATCCTTAT-3; (antisense): 5-
AGGTATCGATCCACAGCAATG-3.
Cochlear explant cultures.Cochleae were extracted from neonatal mice
at postnatal day 3 (P3) to P5 in dissection medium containing 1HBBS
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and 25 mMHEPES, pH 7.5. They were then transferred to a 35 mm Petri
dish containing explant culture media (DMEM with glucose and glu-
tamine  1% FCS  ampicillin and ciprofloxacin) and the organs of
Corti (explants) were isolated. The explants were cultured at 37°C in 5%
CO2 for 1 d before drug treatment.
Morphological studies by cochlear whole-mount preparation. Isolated
adult rat cochleae were perfused with 4% paraformaldehyde and kept
overnight at 4°C in the same solution for fixation. Then, cochleae
were decalcified in 0.1 M EDTA, pH 7.4, with stirring at room tem-
perature for 2 weeks. After decalcification, the cochleae were micro-
dissected into basal, middle, and apical turns for whole-mount
preparation.
Statistical analysis. Data are presented as mean  SEM. Statistical
significance differences among groups were performed by either Stu-
dent’s t test or ANOVA followed by Tukey’s post hoc test wherever
appropriate.
Results
A1ARs are expressed on cochlear OHCs
We have shown previously that the rat cochlea expresses
A1ARs, the activation of which led to inhibition of adenylyl
cyclase activity (Ramkumar et al., 1994), stimulation of anti-
oxidant enzymes, and a reduction in lipid peroxidation (Ford
et al., 1997a). Additional studies have also shown that the
chemotherapeutic agent cisplatin induces the expression of
the cochlear A1AR, which likely represents a compensatory
mechanism by the cochlea to counter the toxic effects of in-
creased ROS generation by cisplatin (Ford et al., 1997b). Ac-
tivation of A1AR was also shown to confer protection of OHCs
against cisplatin-induced damage and death and hearing loss
(Whitworth et al., 2004; Gunewardene et al., 2013). However,
it has been suggested that A1ARs are not localized to OHCs,
but rather are found on IHCs, Deiter’s cells, and spiral gan-
glion (SG) neurons (Vlajkovic et al., 2009). In whole-mount
preparations obtained from adult rats, we show A1AR immu-
noreactivity on both OHCs and IHCs (Fig. 1A), where they
colocalize with myosin VIIA, a marker of hair cells. However,
A1AR immunolabeling was certainly more intense in IHCs, as
reported earlier (Vlajkovic et al., 2007, 2009). Quantification
of immunofluorescence shows A1AR staining in IHCs was
115  5% of that observed in OHCs (mean  SEM, n  4).
Orthogonal sections (Fig. 1B) clearly show staining for the
A1AR in OHCs from rat cochlea. Cisplatin increased the ex-
pression of A1AR in the cochlea, as indicated by qPCR studies
(n 5, Fig. 1C). Interestingly, this effect was attenuated by the
A1AR agonist R-PIA, suggesting that activation of the A1AR
negatively influences its induction by cisplatin. Similarly, we
observed an increase in A1AR immunolabeling of 52  7%
(n  5, p  0.05) in the OHCs 3 d after cisplatin treatment
Figure 1. Presence of A1AR in rat cochlear hair cells. A, Whole-mount preparations of adult rat organ of Corti were stainedwith antibodies against the A1AR,myosin VIIA, or DAPI and imaged by
confocalmicroscopy. High levels of A1AR immunoreactivity was observed in IHCs, with lower levels in OHCs. Similar patterns ofmyosin VIIA immunolabelingwas detected, with a significant degree
of colocalization in IHCs. Orthogonal sections of these images are shown in B and indicate localization of A1AR to IHCs and OHCs with a significant degree of colocalization. C, Rat were treated with
cisplatin (11mg/kg, i.p.), killed 3 d later, and their cochleae were dissected out and processed for RNA and for expression of A1AR by real-time PCR. Cisplatin produced a significant increase in A1AR
expression,whichwasblockedbyR-PIA. PretreatmentwithDPCPXbeforeR-PIA reversed the inhibition of A1AR inductionby cisplatin. *Statistically significant difference fromvehicle-treatedgroup;
**statistically significant difference fromcisplatin-treatedgroup; ***statistically significant difference fromR-PIA-treatedgroup (n5,p0.05).D, Ratswere treatedwith vehicle or cisplatin (11
mg/kg, i.p.), killed3d later, and their cochleaeweredissectedout, decalcifiedover a3weekperiod, andused forwhole-mountpreparations. Thesepreparationswere stainedand imagedby confocal
microscopy. Images of OHCs show increased levels of A1AR immunoreactivity with little change in myosin VIIA.
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(Fig. 1D), but a significant decrease in myosin VIIA immuno-
reactivity of 25  4% (n  5, p  0.05).
Activation of A1AR prevented cisplatin-induced hearing loss
and damage to OHCs
Previous studies have indicated that round window application
of R-PIA reduced cisplatin-induced hearing loss and hair cell
damage (Whitworth et al., 2004). In this study, we showed a
similar effect of R-PIA when administered by the trans-tympanic
route. MaleWistar rats were treated with vehicle or R-PIA (50l
of 0.1 mM solution), followed by intraperitoneal administration
of cisplatin (11 mg/kg) 30 min later. ABRs were assessed imme-
diately before (pretreatment ABRs) and 3 d after cisplatin admin-
istration (posttreatment ABRs). The administration of vehicle
produced minimal change in ABR thresholds from pretreatment
values. Cisplatin elevated thresholds averaged 5  2, 8  3, and
30  2 dB at frequencies of 8, 16, and 32 kHz, respectively (Fig.
2A). However, trans-tympanic R-PIA significantly attenuated
cisplatin-induced changes in ABR thresholds at 8, 16, and 32 kHz
(p  0.05, n  5). The ABR thresholds shifts in the R-PIA 
cisplatin-treated animals were 0, 0, and 3 1 dB for 8, 16, and 32
kHz, respectively, demonstrating a pronounced inhibitory effect
on hearing loss assessed at different frequencies by R-PIA, espe-
cially at the highest frequency. Co-administration of A1AR antag-
onist, DPCPX (50l of 0.1mM solution), completely reversed the
protective effect of R-PIA (Fig. 2A). SEM images of the organ of
Corti obtained from the animals treated above showed extensive
loss of OHCs in the basal turn of the cochleae obtained from
animals treated with cisplatin (Fig. 2B). In addition, the remain-
ing OHCs in the basal turn showed significant disruption in ste-
reociliary bundles. The extent of the loss or damage of OHCs in
the basal turn averaged 77  11% (average of 4 cochleae) com-
pared with vehicle-treated animals (Fig. 2C). In contrast, the or-
gan of Corti obtained from animals pretreated withR-PIA before
cisplatin showed significantly reduced loss or damage ofOHCs in
the basal turn (9 7% loss of OHC). Disruption of stereociliary
bundles was considerably reduced. Cochleae obtained from ani-
mals treated with R-PIA alone showed 7 2% damage in OHC
morphology that was not significantly different from vehicle-
treated and R-PIA  cisplatin-treated rats, which could reflect
damage inherent to the procedure used for sample preparation.
Pretreatment with a combination of DPCPX and R-PIA before
cisplatin resulted in greater loss of OHCs (86  7%) compared
with the vehicle- and cisplatin-alone-treated groups (Fig. 2C),
Figure 2. Activation of the A1AR leads to inhibition of cisplatin-induced hearing loss in rats. A, ABR thresholds were recorded in Wistar rats treated with cisplatin (11 mg/kg, i.p.) after
trans-tympanic administration of R-PIA (1M) or DPCPX (3M) R-PIA. Posttreatment ABRs, determined 3 d later, showed significant elevations in ABR thresholds, which were attenuated by
R-PIA. The protective effect of R-PIAwas reversed byDPCPX,which significantly enhanced the ABR shifts produced by cisplatin at all frequencies tested. Arrows indicate 0 ABR threshold shift.B, SEM
studies performed on the cochleae show significant damage to OHCs (white arrows) by cisplatin, whichwas protected by the A1AR agonist R-PIA and exacerbated by DPCPX. C, Quantitative analysis
of the SEM images.D, DPCPX exacerbates cisplatin-induced loss of OHCswithout affecting IHCs. Cochlear explants from P5micewere treatedwith vehicle, cisplatin, or cisplatinDPCPX (1M) for
48 h, stained formyosin VIIA, and imaged by confocalmicroscopy. E, Expression of A1AR in adultmouse organ of Corti. In these images, red representsmyosin-VIIA and green represents A1AR. Data
inA and C are presented asmean SEM of five rats. Images shown inB andD are representatives of five similar images from different rats. *Statistically significant difference from vehicle-treated
group; **statistically significant difference from cisplatin-treated group; ***statistically significant difference from cisplatin-treated group ( p 0.05, n 5).
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suggesting a partial protective action of the cochlear A1AR acti-
vation by endogenous adenosine in the cisplatin-treated rats.
These findings confirm the utility of trans-tympanic administra-
tion of R-PIA against cisplatin-induced hearing loss. Because the
OHCs express A1ARs, it is it is likely that activation of these
receptors provided the protection afforded by the agonist. How-
ever, it is also possible that protection of the OHCs is mediated
indirectly by reductions in cisplatin-induced damage to other
regions of the cochlea, such as IHCs, stria vascularis (SVA), SG, or
spiral ligament (SL). In addition, a previous study has shown
direct inhibition by AR drugs of TRPV1 channels (Puntambekar
et al., 2004), which are also expressed onOHCs (Mukherjea et al.,
2008). Inhibition of these channels confers protection against
cisplatin-induced hearing loss (Mukherjea et al., 2008).
In most studies, IHCs appear to be resistant to cisplatin-
induced damage. We reasoned that the high expression of the
A1AR in these cells could contribute to this resistance. To exam-
ine the role of the A1AR present on IHCs, we used organ of Corti
explants from P5mice. Explants were allowed to recover for 24 h
in culture after dissection and were then incubated with vehicle,
cisplatin (20M),DPCPX (3M), orDPCPX cisplatin for 48 h.
Cisplatin produced a significant loss of OHCs, with some disrup-
tion of IHCs. Blockade of the A1AR with DPCPX potentiated the
loss of OHCs, but did not significantly affect IHCs (Fig. 2D).
Counting the OHCs per field indicated 	66% loss of myosin
VIIA-stained cells in the cisplatin-treated explants, but 	88%
loss of cells in the DPCPX  cisplatin-treated explants. These
data suggest that activation of the A1ARs expressed on IHCs do
not confer resistance of these cells to cisplatin. Additional immu-
nohistochemical studies indicate that the mouse cochlea ex-
presses A1AR,with higher levels in the IHCs thanOHCs (Fig. 2E).
Similar expression of the A1ARwas observed from the base to the
apex of the cochlea (data not shown).
A1AR activation reduces ROS generation via NOX3
Cisplatin ototoxicity is mediated in part by ROS produced via
NOX3 (Ba´nfi et al., 2004; Mukherjea et al., 2008). ROS regulates
STAT1 phosphorylation in pancreatic cancer cells by maintain-
ing Janus kinase 2 (JAK2) in a constitutively active state (Simon et
al., 1998). In addition, we have also shown that ROS activate
STAT1 via the ERK1/2 pathway (Kaur et al., 2011). Therefore, we
investigated whether R-PIA inhibits ROS generation via NOX3.
These experiments were performed in UB/OC-1 cells, a cell line
derived from the mouse embryonic cochlear hair cells that ex-
press hair cell markers such as Brn 3.1, myosin VIIA, and  9
nicotinic receptor (Rivolta et al., 1998). These cells also express
the A1AR, as depicted by flow cytometry and Western blotting
(Fig. 3A). Exposure of these cells to cisplatin for 24 h increased the
levels of the A1AR protein (Fig. 3A) and mRNA (by 40  4%).
These responses are similar to those observed in the cochlea of
cisplatin-treated rats (Fig. 1D). ROS generation wasmeasured by
live confocal imaging using H2DCFDA dye. Cisplatin increased
Figure 3. R-PIA inhibits cisplatin-induced ROS generation via NOX3. A, UB/OC-1 cells express A1AR receptors that were significantly upregulated by cisplatin. UB/OC-1 cells were exposed to
vehicle or cisplatin (2.5M) for 24 h and processed for flow cytometry using A1AR antibody and forWestern blotting. Cisplatin significantly increased themean fluorescence exhibited by these cells
(1.39 0.04 fold) and this was confirmed by Western blot data showing increased in A1AR protein levels by 27 4% and mRNA by 40 4%. B, ROS generation was measured in UB/OC-1 cells
treated with either R-PIA or DPCPX R-PIA for 0.5 h, followed by treatment with cisplatin (2.5M) for 15 min. Cells were then incubated with 5M H2DCFDA dye for 15 min and ROS generation
(green fluorescence) was visualized by confocal microscopy. DIC, Differential interference contrast. Cisplatin increased NOX3 mRNA in the UB/OC-1 cells (C) and rat cochlea (D), as determined by
quantitative real-time PCR. This responsewasmimicked byH2O2 (100M) treatment for 24 h (E). F,Western blots for NOX3 after treatmentwith cisplatin and/or EGCG (100M) in UB/OC-1 cells for
24 h. Data are presented as mean SEM of at least four independent experiments. *Statistically significant difference from vehicle-treated group; **statistically significant difference from
cisplatin-treated group ( p 0.05).
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the ROS levels in the cells, as indicated by enhanced green fluo-
rescence compared with vehicle-treated cells (Fig. 3A). The ROS
generation by cisplatin was inhibited by pretreatment withR-PIA
(Fig. 3B). R-PIA also attenuated NOX3 expression induced by
cisplatin both in UB/OC-1 cells (Fig. 3C) and in the rat cochlea
(Fig. 3D), suggesting that the A1AR can regulate ROS generation
by controlling both the activity and expression of theNOX3 gene.
Accordingly, by acting on the A1AR, adenosine could serve as an
endogenous inhibitor of NOX3 activity and expression. Interest-
ingly, ROS positively regulates the expression of A1AR (Nie et al.,
1998). To confirm that ROS could induce NOX3 expression, we
exposed UB/OC-1 cells to H2O2 and measured the expression of
NOX3 by real-time PCR. We observed a 1.5 0.1-fold increase
in NOX3 when UB/OC-1 cells were exposed to 100 MH2O2 for
24 h (Fig. 3E). Furthermore, to determine a possible mechanism
of induction of NOX3, we inhibited STAT1 using EGCG (100
M), a known inhibitor of this transcription factor. Data pre-
sented in Figure 3F show that EGCG inhibited the induction of
NOX3 by cisplatin. These data suggest a reciprocal interaction
between NOX3 and STAT1 in the cochlea.
A1AR inhibits cisplatin-induced activation of STAT1 in UB/
OC-1 cells and rat cochlea
Several studies have implicated the STAT1 transcription factor in
mediating an inflammatory process in the inner ear resulting in
hearing loss (Schmitt et al., 2009; Mukherjea et al., 2011; Kaur et
al., 2011). We have also shown previously that cisplatin-induced
STAT1 activation is mediated via ROS generation (Mukherjea et
al., 2011). Because activation of A1AR inhibits ROS generation,
we investigated whether it also inhibits cisplatin-induced STAT1
activation. For these experiments, UB/OC-1 cells were pretreated
with R-PIA (1M), followed by cisplatin (2.5M), for 45min. The
levels of Ser727-phosphorylated STAT1 (Ser727 p-STAT1) were in-
creased by	40%comparedwith vehicle-treated cells.R-PIA signif-
icantly reduced the cisplatin-induced Ser727 p-STAT1 levelswithout
altering the levels of total STAT1. Co-administration of DPCPX (3
M)withR-PIA (1M) led to complete reversal ofR-PIA-mediated
inhibition of STAT1 activation produced by cisplatin (Fig. 4A).
However, co-administrationofZM241385 (3M), anA2AARrecep-
tor antagonist, orMRS1523 (3M), anA3AR antagonist, alongwith
R-PIA did not inhibit the effect of R-PIA (data not shown). To-
Figure 4. Cisplatin activation of STAT1 is attenuated by R-PIA in UB/OC-1 cells.A, UB/OC-1 cells were treatedwith R-PIA for 0.5 h before cisplatin treatment for 45min. Cell lysateswere prepared
and used inWestern blot studies for Ser 727 p-STAT1.B, UB/OC-1 cells were pretreatedwith R-PIA or DPCPX R-PIA for 0.5 h, followed by cisplatin treatment for 45min. Cells were then fixedwith
4%paraformaldehyde and stainedwith p-STAT1 antibody, followed by a fluorescein-tagged secondary antibody (green). Cisplatin increased p-STAT1 immunoreactivity in the UB/OC-1 cells, which
coincided significantly with nuclei as seen in fluorescent images. Nuclear translocation of p-STAT1 was not observed in cells pretreated with vehicle, R-PIA, and DPCPX treatment alone. This is a
representative of three experiments showing similar results. C, UB/OC-1 cells were transfected with a plasmid vector encoding STAT1 luciferase, along with a Renilla luciferase. After 36 h of
transfection, the cells were treated with R-PIA and DPCPX, followed by treatment with vehicle or cisplatin (2.5M) for 8 h. Lysates were prepared and used for determination of luciferase activity.
Cotransfection of a plasmid expressing renilla luciferase allowed for normalization of luciferase activity in eachwell.D, UB/OC-1 cellswere treatedwith R-PIA for 0.5 h, followed by cisplatin (2.5M)
for 24 h. RNAwas isolated using TRIzol reagent andmRNA levels of TNF-, iNOS, and COX-2were determined by real-time RT-PCR. GAPDHwas used as a housekeeping gene and for normalization.
E,R-PIA reduced IFN-mediated STAT1 activity on Ser 727, but not on the Tyr 701, phosphorylation site. Cellswere exposed toR-PIA (1M) for 0.5 h, followedby treatmentwith IFN- (250 units/ml)
for 1 h. Cells lysates were subjected to immunoblotting for Ser 727 and Tyr 701 p-STAT1. Data are presented as mean SEM of three independent experiments. *Statistically significant difference
from vehicle-treated group; **statistically significant difference from cisplatin-treated group ( p 0.05, n 3).
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gether, these data suggest that inhibition of STAT1 by R-PIA is me-
diated specifically by the A1AR subtype.We did not examine Tyr
701
p-STAT1because cisplatinwas unable to induce phosphorylationof
this site (Kaur et al., 2011).
Cisplatin increased nuclear translocation of p-STAT1 within
45min, as indicated by increased nuclear immunolabeling, com-
pared with vehicle-treated cells. Nuclear Ser727 p-STAT1 labeling
(green color) was more intense in the cisplatin-treated cells com-
pared with R-PIA alone or R-PIA  cisplatin-treated cells (Fig.
4B). The effect of R-PIA was blocked by DPCPX, implicating the
A1AR in this process. Cisplatin also increased STAT1 luciferase
activity by 2.7 0.3 fold, which was attenuated by R-PIA (1.0
0.1-fold; Fig. 4C). Co-administration of DPCPX reversed the ef-
fect ofR-PIA, as evidenced by increased STAT1 luciferase activity
of 2.4 0.4 fold (Fig. 4C). R-PIA also attenuated the expression
of STAT1-regulated genes, such as TNF-, iNOS, and COX-2
(Fig. 4D). Cisplatin significantly increased the mRNA levels of
TNF-, iNOS, and COX-2 by 2.4 0.2, 2.8 0.1, and 2.2 0.1
fold, respectively, whereas pretreatment with R-PIA attenuated
the respective increases to 1.4 0.3, 1.4 0.2, and 1.6 0.1 fold
(statistically significant inhibition for all groups, p  0.05).
DPCPX not only blocked the effect of R-PIA, but also enhanced
the expression of TNF-, iNOS, and COX-2 by 3.4 0.1, 3.1
0.1, and 2.3 0.2, respectively. The effect ofDPCPXon cisplatin-
induced TNF- expression was statistically significantly different
from that of cisplatin alone (p 0.05), suggesting tonic suppres-
sion of the expression of this cytokine by endogenous adenosine
via the A1AR (Fig. 4D). We investigated whether R-PIA would
also affect the response of interferon- (IFN-), a known activa-
tor of STAT1. Treatment of UB/OC-1 cells with IFN- (250
units/ml) increased phosphorylation of STAT1 at both Ser727 and
Tyr701 by 3- and 2-fold, respectively, compared with vehicle-
treated cells. In cells pretreated with R-PIA (1 M), the IFN-
phosphorylation of Ser727 STAT1 was reduced to 	1.5 fold,
whereas the increased Tyr701 phosphorylation was unaffected
(Fig. 4E). These data suggest that activation of A1AR specifically
inhibits the Ser727, but not the Tyr701, phosphorylation of
STAT1, which could contribute to the inhibition of expression of
STAT1 responsive genes. Accordingly, the ototoxicity produced
by cisplatin and attenuated by A1AR is attributable, at least in
part, to phosphorylation of STAT1 at Ser727.
Previous studies from our laboratory showed that cisplatin
increased Ser727 p-STAT1 immunolabeling in the rat cochlea.
Increased immunolabeling was observed in the OHCs, SG, and
SVA (Kaur et al., 2011). We next determined whether trans-
tympanic administration of R-PIA in rats could inhibit Ser727
p-STAT1 immunolabeling in the rat cochlea. Immunolabeling
for Ser727 p-STAT1 showed low baseline Ser727 p-STAT1 immu-
Figure 5. Cisplatin-induced activation of STAT1 is attenuated by R-PIA in the rat cochlea. A, Immunolabeling studies were performed on the cochlear sections isolated from the rats treatedwith
vehicle or cisplatin (11mg/kg/i.p.) for 72 h after trans-tympanic administration of R-PIA (1M). Ser 727 p-STAT1 immunolabeling is indicated by green fluorescence while cell nuclei are defined by
DAPI staining. Statistically significant increases in immunofluorescenceareobserved in theOHCs (OHC) and spiral ganglion (SG) cells. Scalebar shown in the lower rightpanel is 100m.B,Magnified
view of the OHC from the square boxes in (A). Arrows indicate the three rows of OHCs. DC represents Deiter’s cells. Scale bar shown in the lower right panel is 10m. C, Quantification of p-STAT1
immunofluorescence from (A, B). D, Total STAT1 mRNA, determined by real time PCR, was not changed with any of the treatment groups in cochleae obtained from rats. Data are presented as
mean SEM (n 5). *Statistically significant difference from vehicle-treated group; **statistically significant difference from cisplatin-treated group ( p 0.05).
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noreactivity in the cochleae from rats administered vehicle,
R-PIA, and DPCPX alone. Cisplatin increased Ser727 p-STAT1
immunoreactivity in the cochleae, which was reduced by pre-
treatment with R-PIA (Fig. 5A). Increases in Ser727 p-STAT1
immunoreactivity induced by cisplatin were observed in the
OHCs and SG cells, with no significant changes observed in SVA
and SL cells (Fig. 5B). These increases were attenuated by R-PIA.
Co-administration of DPCPX and R-PIA before cisplatin not
only attenuated the effect of R-PIA, but further increased Ser727
p-STAT1 immunolabeling in the OHCs, but not in other regions
(Fig. 5B). Higher-magnification images indicate increased label-
ing of the OHC after cisplatin or cisplatinDPCPX treatments.
Staining was also observed in regions below the OHCs, possibly
reflecting labeling ofDeiter’s cells (Fig. 5C). Immunolabelingwas
also prominent in the basilar membrane. The levels of STAT1
mRNA remained unchanged after cisplatin treatment (Fig. 5D),
suggesting that cisplatin activated, but did not induce, the expres-
sion of total STAT1 over this time period.
Activation of A1AR reduces cisplatin-induced inflammation
Adenosine regulates a variety of pathophysiological processes in-
volving neuronal damage or death (Ribeiro et al., 2002) and in-
flammation (Cronstein, 1994). In recent studies, the activation of
ARs on immune cells suppressed the production of proinflam-
matory mediators, including TNF- (Bouma et al., 1994; Hasko´
et al., 1996; Sajjadi et al., 1996). In addition, Tsutsui et al. (2004)
demonstrated that spinal cords from A1AR knock-out mice had
increased proinflammatory gene expression during experimental
allergic encephalomyelitis. Macrophages derived from A1AR
knock-out animals exhibited increased expression of the proin-
flammatory genes, such as interleukin-1 (IL-1) and iNOS,
upon immune activation compared with wild-type control mice.
In a previous study, we showed that STAT1-induced inflamma-
tion is an important contributor to cisplatin ototoxicity (Kaur et
al., 2011). BecauseR-PIA attenuated cisplatin-induced activation
of STAT1 (Figs. 4, 5), these findings suggest thatR-PIA-mediated
otoprotection could similarly involve inhibition of STAT1-
Figure 6. Adenosine A1 receptor activation attenuates cisplatin-induced inflammation in rat cochlea. A, Rats were treated with R-PIA or DPCPX R-PIA by trans-tympanic injections, followed
by vehicle or cisplatin (11mg/kg, i.p.). Ratswere killed 3d after the administration of vehicle or cisplatin. The cochleaewere excised andprocessed for immunohistochemistry.Mid-modiolar sections
of the cochleawere labeledwith TNF- antibodies, followedby fluorescein (green)-labeled secondary antibodies andDAPI staining to label thenucleus. Cisplatin increased TNF- immunoreactivity
in cochleae treated with cisplatin. However, the increases in immunolabeling were attenuated in cochlea pretreated with R-PIA. Scale bars (right bottom), 100m. B, Magnified view of the OHCs
presented in A. Arrows indicate three rows of OHCs. DC, Deiter’s cells. Increased TNF- immunoreactivity was observed in both OHCs and Deiter’s cells. Scale bar, 10m. C, TNF-mRNA levels in
the rat cochleawere determined by real-time PCR. Cisplatin induced increase in themRNA levelswere reduced byR-PIA pretreatment. Trans-tympanic administration of DPCPX, anA1AR antagonist,
reversed the effects of R-PIA. D, Quantification of TNF- immunoreactivity in different regions of the organ of Corti after different treatments. Data are presented as mean SEM. *Statistically
significant difference from vehicle-treated group; **statistically significant difference from vehicle cisplatin-treated group ( p 0.05, n 5).
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regulated inflammatory pathways. To determine whether R-PIA
prevented cisplatin-induced inflammation in vivo, we examined
the levels of TNF- in the cochlea by immunohistochemistry.
High TNF- immunolabeling was observed 3 d after administra-
tion of cisplatin in the SG and OHCs, but not in the SVA or SL,
compared with vehicle-treated rats. Trans-tympanic administra-
tion of R-PIA suppressed the increases in the immunolabeling of
TNF- (Fig. 6A). R-PIA also suppressed cisplatin-induced
TNF- mRNA levels from whole cochlear RNA preparations.
Cisplatin induced a	3.1 0.5 fold increase in the expression of
TNF- in the cochlea, and this was attenuated by trans-tympanic
administration of R-PIA (0.37  0.3 fold; Fig. 6C). Blockade of
the A1AR with DPCPX led to reversal of the anti-inflammatory
effect of R-PIA and to potentiation of cisplatin-induced TNF-
immunolabeling in the SVA and SL (Fig. 6A,B,D). A similar
pattern of changes was observed at the mRNA level (Fig. 6C).
These data indicate that the OHCs and SG cells could produce
cytokines (e.g., TNF-) in response to cisplatin and that the pro-
duction of these cytokines is under the control of A1AR present
on these cells. The finding that activation of theA1AR reduced the
levels of TNF- from these various regions of the cochlea suggests
that increases in TNF- in these regions might contribute to the
overall inflammation and hearing loss produced by cisplatin and
also support previous findings that inhibition of TNF- by etan-
ercept reduced cisplatin-induced hearing loss (Kaur et al., 2011).
Activation of A1AR attenuates cisplatin-mediated apoptosis
Treatment with cisplatin increases cochlear cell apoptosis
(Mukherjea et al., 2008). We have shown previously that STAT1
is the key regulator of cisplatin-induced apoptosis both in vitro
and in vivo by activating the classical apoptotic pathway directly
(Kaur et al., 2011). Induction of apoptotic markers involves the
Ser727 p-STAT1 instead of Tyr701 p-STAT1 phosphorylation
(Stephanou et al., 2001). Results, described above, indicated that
R-PIA targeted Ser727, but not Tyr701, for inhibition. Therefore,
we investigated whether R-PIA also inhibits cisplatin-mediated
apoptosis. UB/OC-1 cells were pretreated with R-PIA (1 M)
before cisplatin administration (20 M) for 24 h. The percentage
of apoptotic cells measured by Annexin V staining increased
from	9% for vehicle-treated cells to	40% for cisplatin-treated
Figure 7. R-PIA reduced cisplatin-mediated apoptosis of UB/OC-1 cells. A, UB/OC-1 cells were treated with R-PIA for 0.5 h, followed by cisplatin (20M) for an additional 24 h. Apoptosis was
determinedbymeasuring thepercentageofAnnexin-positive andAnnexinplus propidium iodide-positive cells (lower right andupper right quadrant, respectively) by flowcytometry.B, Percentage
of apoptotic cells for each treatment as determined inA and plotted as themean SEM (n 3). *Statistically significant difference fromvehicle-treated group; **statistically significant difference
from vehicle cisplatin-treated group ( p 0.05). C, UB/OC-1 cells were treatedwith R-PIA for 0.5 h, followed by cisplatin (20M) for an additional 24 h. Cells lysates were used to determine the
levels of cleaved caspase 3, Bcl2, and -actin (for normalization). Cisplatin induced the cleavage of procaspase-3, which was attenuated by R-PIA. R-PIA prevented the downregulation of
anti-apoptotic protein Bcl2 induced by cisplatin treatment. The figure shown is a representative of four similar experiments showing similar results.
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cells. The increase in apoptosis produced by cisplatin was abol-
ished byR-PIA (Fig. 7A,B). An interesting observation was that a
larger percentage of UB/OC-1 cells that were Annexin V positive
(apoptotic) expressed A1AR than cells that were Annexin V neg-
ative (47  3% of apoptotic cells vs 30  2% of cells that were
Annexin V negative). One explanation for these data is that cells
that ultimately became apoptotic increased their output of A1AR
in a futile effort to survive compared with cells that survived
cisplatin. These data also suggest that the levels of A1AR on UB/
OC-1 cells alone do not dictate the survival of these cells against
cisplatin; rather, it is the activation of the A1AR by agonist that
was a key to survival.
Cisplatin-induced cleavage of pro-caspase 3 to caspase 3 was
also abolished by R-PIA (Fig. 7C). Cells exposed to cisplatin
showed reductions in Bcl2 thatwere inhibited byR-PIA (Fig. 7C).
R-PIA also reduced cisplatin-induced p-53 induction (data not
Figure 8. R-PIA reduced cisplatin-mediated apoptosis in the rat cochlea. TUNEL assay was performed on the cochlear section isolated fromWistar rats treated with trans-tympanic injection of
R-PIA (1M) for 0.5 h, followed by vehicle or cisplatin (11mg/kg) administration, and assessed 3 d later. Cisplatin increased the TUNEL-positive staining in the OHCs, Deiter’ cells (DC), and SGs (see
the higher magnification in the bottom). R-PIA pretreatment reduced the TUNEL-positive staining induced by cisplatin and DPCPX reversed the protective effect of R-PIA. DPCPX also produced
nuclear fragmentation inOHCs andDeiter’s cells from the cisplatin-treated cells rats (see red arrows). Top scale bar, 100m.Magnified viewof theOHCs and SGs is presented in bottom three panels.
White arrows indicate three rows of OHCs. Bottom scale bar, 10m.
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shown) and prevented cisplatin-induced apoptosis in the organ
of Corti of Wistar rats, as measured by TUNEL staining (Fig. 8).
Cisplatin produced damage to the OHCs, SG, SL, and SVA, as
depicted by green fluorescent staining, indicating TUNEL-
positive cells. Trans-tympanic administration of R-PIA before
cisplatin treatment reduced the number of TUNEL-positive cells
in the respective areas of the organ of Corti mentioned above
(Fig. 8). At highermagnification, intense Annexin–FITC labeling
was observed in both OHCs and Deiter’s cells. R-PIA-mediated
protection against cisplatin apoptosis was abolished by DPCPX.
Increased nuclear fragments were observed inOHCs andDeiter’s
cells stained in the cisplatin  DPCPX-treated cochleae com-
pared with cisplatin-treated cochleae (Fig. 8, middle two panels).
These data implicate the A1AR in suppressing cisplatin-induced
apoptotic of cochlear cells. The finding of greater nuclear damage
induced by cisplatin in the presence of DPCPX suggests that the
A1ARprovides some level of tonic suppression of apoptosis in the
cochlea. Similar findings were observed in the SG neurons, in
which cisplatin-increased apoptosis was blocked by R-PIA,
whereas this protective action was abolished by DPCPX (Fig. 8,
bottom three panels).
A1AR reduces STAT1 activation by inhibition of MAPKs
Serine phosphorylation was first described for STAT1, STAT3,
and STAT4 due to presence of amitogen-activated protein kinase
(MAPK) consensus sequence, PMSP, at the C-terminal tail at
Ser727 for STAT1 (Zhang et al., 1995) and STAT3 (Wen et al.,
1995). Phosphorylation of Ser727 STAT1 could be achieved by
serine kinases such as the MAPKs, ERK 1/2 (David et al., 1995;
Jain et al., 1998), p38 (Turkson et al., 1999; Zauberman et al.,
1999), and JNK (Lim and Cao, 1999; Turkson et al., 1999). Phos-
phorylation could also be mediated by PKC- (Jain et al., 1999)
or PKC- (Aziz et al., 2010). A number of studies have implicated
ERK1/2 and p38 in cisplatin-mediated damage to the auditory
hair cells (Wu et al., 2005; Previati et al., 2007; So et al., 2007; So
et al., 2008; Abi-Hachem et al., 2010; Lee et al., 2010; Tabuchi et
al., 2011). We therefore, hypothesized that cisplatin increases
Ser727 p-STAT1 via the MAPK pathway. To test our hypothesis,
we determined the effect of cisplatin on activation of MAPKs in
UB/OC-1 cells. Cisplatin (2.5 M) increased the activity of
ERK1/2, JNK and p38. Phosphorylation of ERK 1/2 and JNK
started 45 min following cisplatin administration and remained
elevated up to 120 min, whereas p38 phosphorylation started
Figure 9. R-PIA inhibits STAT1 activity by decreasing MAPK activation. A, UB/OC-1 cells were treated with cisplatin (2.5M) and the phosphorylation of ERK1/2, p38, and JNK1 were evaluated
at 0, 15, 30, 45, 60, and120min. The respective phosphorylatedMAPKwasnormalized to its total protein level.B, TheMAPK inhibitors SB230580, PD98059, andSP600125 reduced cisplatin-induced
STAT1 phosphorylation. C, MAPK inhibitors reduced cisplatin-induced STAT1 luciferase activity. Data are presented as themean SEMof four experiments. *Statistically significant difference from
control ( p 0.05); ** statistically significant difference from the cisplatin-treated group ( p 0.05). D, MAPK inhibitors reduced the IFN--activated Ser 727 p-STAT1, but not Tyr 701 STAT1
phosphorylation.E,R-PIA inhibited cisplatin-inducedactivationof ERK1/2, p38, and JNKphosphorylation.F,MAPK inhibitors reduced cisplatin-inducedapoptosis ofUB/OC-1 cells. Cellswere treated
with vehicle or 20M cisplatin or a combination of cisplatinMAPK inhibitors. Results shown in A, B, D, and E are each a representative of a single experiment that was replicated at least three
times. Data are presented as the mean SEM of four experiments. *Statistically significant difference from control ( p 0.05); **statistically significant difference from cisplatin-treated group
( p 0.05).
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within 15min and remained elevated up to 45min before return-
ing to baseline (Fig. 9A). Pretreatment of UB/OC-1 cells with
inhibitors of ERK 1/2 (PD98059), p38 (SB230580), and JNK
(SP600125) reduced cisplatin increased Ser727 p-STAT1 levels
(Fig. 9B). PD96059, SB230580 and SP600125 also reduced
cisplatin-induced STAT1 luciferase activity in UB/OC-1 cells
(Fig. 9C). Similar to the results with cisplatin, inhibition of
ERK1/2, p38 and JNK reduced IFN- induced Ser727 but not
Tyr701 p-STAT1 (Fig. 9D), suggesting that the MAPKs regulate
mainly the Ser727 phosphorylation of STAT1. Furthermore, we
show thatR-PIA (1M) reduced cisplatin-mediated activation of
ERK1/2, p38, and JNK. These effects were reversed by DPCPX,
implicating A1AR in these processes (Fig. 9E). Overall, these data
suggest that the protective action of the A1AR against cisplatin
activation of STAT1 involves inhibition of the MAPK pathways.
Additional studies were performed to determine whether MAPK
inhibitors protect against cisplatin-induced apoptosis. Pretreat-
ment of UB/OC-1 cells with SB230580 (10 M), PD98059 (10
M), or SP600125 (10 M), followed by cisplatin (20 M), led to
significant reductions in apoptosis of UB/OC-1 cells. Cisplatin
increased cell apoptosis to 47  1%, whereas SB230580,
PD98059, and SP600125 reduced the levels of apoptosis to 18.8
0.2, 24.7 0.8, and 23.1 0.1%, respectively (Fig. 9F).
Discussion
The major finding of this study is that the A1AR subserves an
anti-inflammatory role in the cochlea that contributes to its abil-
ity to protect against cisplatin-induced hearing loss. This process
primarily involves inhibition of ROS generation via NOX3
NADPH oxidase, which leads to inhibition of the STAT1 tran-
scription factor and reduced expression of inflammatory media-
tors and pro-apoptotic proteins. Therefore, drugs that boost the
levels of endogenous adenosine or activate the A1AR directly
could play a pivitol role in the survival of cells in the organ of
Corti against cisplatin-mediated apoptosis. Therefore, the A1AR
could serve as an ideal target for otoprotective therapy against
cisplatin-induced hearing loss.
The current study extends previous studies showing that acti-
vation of the A1AR protects against cisplatin-induced ototoxicity
in the chinchilla (Ford et al., 1997b) and rat (Whitworth et al.,
2004). In the latter study, protectionwasmediated specifically via
the A1AR, without contribution from other AR subtypes. This
specificity is likely linked to the expression pattern of ARs in the
cochlea, with the A1AR being the most abundant (Ramkumar et
al., 1994). It has also been shown that the adenosine analog
ADAC protected the cochlea against cisplatin-induced loss of
OHCs and hearing loss (Gunewardene et al., 2013). The protec-
tive role of the A1AR in the cochlea was reported to be due to its
ability to increase antioxidant enzymes, leading to decreased lipid
peroxidation (Ford et al., 1997a). This mechanism of protection
appears quite plausible because administration of antioxidants
reduces cisplatin ototoxicity (Rybak et al., 2007). The broader
significance of a ROS hypothesis for mediating hearing loss was
not completely appreciated at that time. However, our recent
studies have provided a link betweenROS generation and inflam-
mation in the cochlea. We have shown that STAT1 couples ROS
generation to cisplatin-induced inflammation in the cochlea
(Mukherjea et al., 2011; Kaur et al., 2011). ROS mediate STAT1
Ser727 phosphorylation, but not Tyr701 phosphorylation (Kaur et
al., 2011). Ser727 p-STAT1 interacts positively with p53 to en-
hance cell apoptosis. These studies clearly identified STAT1 as a
critical factor in mediating cisplatin ototoxicity by regulating in-
flammatory and apoptotic processes. Accordingly, downregula-
tion of STAT1 (by siRNA) or inhibition of TNF- (by etanercept)
protected against cisplatin-induced hearing loss (Kaur et al.,
2011).
In the current study, we determined whether activation of the
A1AR regulates these cisplatin-induced ROS, inflammatory and
apoptotic pathways. Our data identified NOX3 NADPH oxidase
as a major target of inhibition by the A1AR. The A1AR inhibited
NOX3 activity and reduced its expression, which could reduce
the overall oxidative stress in the cochlea and highlight NOX3 as
a novel target of the A1AR. This finding is highly significant in
light of the current therapeutic strategy to inhibit NOX3 by small
molecules for treating hearing loss (Rybak et al., 2012; Rousset et
al., 2015). We show that ROS stimulate MAPKs (ERK1/2, p38,
and JNK), which activate Ser727 p-STAT1 and its transcriptional
activity through distinct phosphorylation sites for ERK1/2 and
p38 identified in the STAT1 protein sequence. These data suggest
a specific role of Ser727 p-STAT1 in mediating cisplatin ototoxic-
ity and as a target for the otoprotective action of the A1AR. The
localization of the A1AR responsible for protection of OHCs
against cisplatin-induced apoptosis is controversial. Previous
studies indicated that the A1AR is localized primarily to the IHCs,
Deiter’s cells, and SG neurons (Vlajkovic et al., 2009). We show
the presence of A1AR, albeit at lower levels, on OHCs. Therefore,
it is reasonable to conclude that protection of OHCs and preser-
vation of hearing is mediated, at least in part, through activation
of A1AR present on OHCs. However, it is possible protection of
the OHCs is also mediated by A1AR present on Deiter’s cells,
which also express A1AR (Vlajkovic et al., 2009) through some
intercellular processes. We observed that cisplatin increased the
levels of TNF- and apoptosis of Deiter’s cells that were inhibited
by activation of the A1AR. Protection of Deiter’s cells would lead
indirectly to protection ofOHCs (May et al., 2013). Cisplatin also
Figure10. Proposedmodel of A1ARprotection against cisplatin-induced ototoxicity. Cispla-
tin activates and induces NOX3, which triggers MAPK and STAT1 activation. STAT1 increases
cochlear inflammation (productionof TNF-, iNOS, andCOX-2),which contributes to apoptosis.
A1AR reduction of cisplatin-induced apoptosis could also result from a direct reduction in DNA
damage (as assessed by reduction in cleaved caspase).
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produced a global increase in TNF-, which could contribute to
the overall inflammatory stress experienced by the OHCs.
Although the OHCs were sensitive to cisplatin, the IHCs were
relatively resistant to this drug (Nakai et al., 1982). We reasoned
that the A1AR present on IHCs could contribute to their resis-
tance to cisplatin. However, blockade of the A1AR in neonatal
organ of Corti explant cultures enhanced loss of OHCs, but did
not affect the number of IHCs. Therefore, other mechanisms
underlying resistance of IHCs to cisplatin have to be invoked. An
interesting observation is that the IHCs express a high-affinity
thiamine transporter, disruption of which leads to selective loss
of these cells (Liberman et al., 2006). An accumulation of thia-
mine, a potential scavenger of cisplatin, into these cells might
render them resistant to cisplatin. Lower levels of expression of
SLC19A2 in OHCs (Fleming et al., 2001) could render them less
able to detoxify cisplatin and thus succumb to this drug. It is also
possible that OHCs and IHCs express different platinum influx
and efflux transporters that could regulate the steady-state drug
levels.
Cisplatin-derived ROS increased the expression of the A1AR
by activating NF-B (Nie et al., 1998), which could serve as a
compensatory mechanism to reduce the toxicity of cisplatin.
Other studies support a role of the ROS/NF-B axis in the regu-
lation of the A1AR by oxidative stress (Pingle et al., 2004; Jajoo et
al., 2006; Basheer et al., 2007; Pingle et al., 2007).
Localized trans-tympanic administration of R-PIA is needed
for otoprotection to avoid potential systemic side effects of this
drug. However, the recent observation that another A1AR ago-
nist, adenosine amine congener, is otoprotective when adminis-
tered systemically could facilitate the testing of this latter agent
for otoprotection in human (Vlajkovic et al., 2010; Gunewardene
et al., 2013). Complications of using adenosine analogs systemi-
cally for treating cisplatin-induced hearing loss are predicted car-
diovascular and CNS side effects, along with the possibility that
these drugs could interfere with cisplatin chemotherapeutic effi-
cacy. Previous studies indicate differing roles of the A1AR in dif-
ferent cancers. Activation of the A1AR suppresses CW2 human
colon cancer growth (Saito et al., 2010), but promotes the growth
of breast cancer cells (Mirza et al., 2005). These findings suggest
limiting the systemic use of A1ARdrugswhen patients are admin-
istered cancer chemotherapeutic drugs such as cisplatin.
In a previous study (Kaur et al., 2011), we observed intense
staining for immune cell markers (such as TNF-) in the SVA,
OHCs, SG, and SL after cisplatin administration (Kaur et al.,
2011). These data are somewhat different from the current find-
ings, which show no statistically significant increase in TNF-
immunoreactivity in the SVA and SL induced by cisplatin. How-
ever, increases in TNF- levels were observed after the adminis-
tration of cisplatin with DPCPX to inhibit the A1AR. One
explanation for the difference is that the conclusion from the
previous study was based on visual inspection of the different
regions for TNF- immunofluorescence, whereas the current
findings are based on actual quantification of the immunofluro-
scence. Secretion of inflammatory cytokines cells in the SG cells,
SVA, and SL could increase the overall TNF- levels experienced
by cells in the organ of Corti. The expression of these immune
markers was reduced by A1AR activation at these locations, sug-
gesting a functional anti-inflammatory role of this receptor at
these locations in the cochlea. In several experiments, we showed
that the addition of the A1AR antagonist DPCPX not only
blocked the protective effects of the agonist, but also potentiated
cisplatin-induced ototoxicity, implying an active role of the en-
dogenous A1AR signaling system in otoprotection. Certainly, this
endogenous system is only partially effective against cisplatin-
induced ototoxicity and requires exogenous agonist to become
fully effective. However, such an endogenous system could be
protective against lower levels of oxidative and inflammatory
stressors.
An obvious limitation of our study is that the findings ob-
tained in UB/OC-1 cultures, derived from an embryonic mouse
hair cell precursor line, might not be relevant to the adult rat
cochlea. However, in most cases, the biochemical findings ob-
served in these studies using UB/OC-1 cultures matched those
observed in the rat cochlea. This suggests that, within the scope of
this study, the UB/OC-1 cells were a relevant in vitromodel with
which to study the cochlea.
In summary, the current data show that the cochlea expresses
A1AR, whichmediates tonic suppression of oxidative, inflamma-
tory, and apoptotic processes. Administration of anA1AR agonist
enhances the protective role of adenosine and protects against
cisplatin ototoxicity by inhibiting the NOX3/STAT1 signaling
pathway. Protection is conferred primarily through suppression
of cochlear oxidative stress and inflammation, which could initi-
ate apoptosis of OHCs. In addition, protection could also be
mediated through regulation of DNA damage/repair processes
that reduce apoptosis (Fig. 10). Therefore, we propose that local-
ized delivery of A1AR agonists could serve as effective adjuncts to
cisplatin chemotherapy to reduce the high degree of hearing loss
observed in cancer patients treated with this drug regimen.
References
Abi-HachemRN, Zine A, VanDeWater TR (2010) The injured cochlea as a
target for inflammatory processes, initiation of cell death pathways and
application of related otoprotectives strategies. Recent Pat CNS Drug
Discov 5:147–163. CrossRef Medline
AzizMH,Hafeez BB, Sand JM, PierceDB,Aziz SW,DreckschmidtNE,Verma
AK (2010) Protein kinase Cvarepsilon mediates Stat3Ser727 phosphor-
ylation, Stat3-regulated gene expression, and cell invasion in various hu-
man cancer cell lines through integration with MAPK cascade (RAF-1,
MEK1/2, and ERK1/2). Oncogene 29:3100–3109. CrossRef Medline
Ba´nfi B, Malgrange B, Knisz J, Steger K, Dubois-Dauphin M, Krause KH
(2004) NOX3, a superoxide-generatingNADPHoxidase of the inner ear.
J Biol Chem 279:46065–46072. CrossRef Medline
Basheer R, Bauer A, Elmenhorst D, Ramesh V, McCarley RW (2007) Sleep
deprivation upregulates A1 adenosine receptors in the rat basal forebrain.
Neuroreport 18:1895–1899. CrossRef Medline
Boison D (2006) Adenosine kinase, epilepsy and stroke: mechanisms and
therapies. Trends Pharmacol Sci 27:652–658. CrossRef Medline
Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA (1994) Dif-
ferential regulatory effects of adenosine on cytokine release by activated
human monocytes. J Immunol 153:4159–4168. Medline
Bryant GM, Barron SE, Norris CH, Guth PS (1987) Adenosine is a modu-
lator of hair cell-afferent neurotransmission. Hear Res 30:231–237.
CrossRef Medline
Cronstein BN (1994) Adenosine, an endogenous anti-inflammatory agent.
J Appl Physiol 76:5–13. Medline
Daval JL, Von Lubitz DK, Deckert J, Redmond DJ, Marangos PJ (1989)
Protective effect of cyclohexyladenosine on adenosine A1-receptors, gua-
nine nucleotide and forskolin binding sites following transient brain
ischemia: a quantitative autoradiographic study. Brain Res 491:212–226.
CrossRef Medline
DavidM, Petricoin E 3rd, Benjamin C, Pine R,WeberMJ, Larner AC (1995)
Requirement for MAPK (ERK2) activity in interferon alpha- and inter-
feron beta-stimulated gene expression through STAT proteins. Science
269:1721–1723. CrossRef Medline
De Sarro G, De Sarro A, Meldrum BS (1991) Anticonvulsant action of
2-chloroadenosine injected focally into the inferior colliculus and sub-
stantia nigra. Eur J Pharmacol 194:145–152. CrossRef Medline
Fedele DE, Li T, Lan JQ, Fredholm BB, Boison D (2006) Adenosine A1
receptors are crucial in keeping an epileptic focus localized. Exp Neurol
200:184–190. CrossRef Medline
Kaur, Borse et al. • A1AR and Cisplatin Ototoxicity J. Neurosci., April 6, 2016 • 36(14):3962–3977 • 3975
Fleming JC, SteinkampMP, Kawatsuji R, Tartaglini E, Pinkus JL, Pinkus GS,
Fleming MD, Neufeld EJ (2001) Characterization of murine high-
affinity thiamine transporter, Slc19a2. Mol Genet Metab 74:273–280.
CrossRef Medline
Ford MS, Maggirwar SB, Rybak LP, Whitworth C, Ramkumar V (1997a)
Expression and function of adenosine receptors in the chinchilla cochlea.
Hear Res 105:130–140. CrossRef Medline
Ford MS, Nie Z, Whitworth C, Rybak LP, Ramkumar V (1997b) Up-
regulation of adenosine receptors in the cochlea by cisplatin. Hear Res
111:143–152. CrossRef Medline
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Mu¨ller CE (2011) In-
ternational Union of Basic and Clinical Pharmacology. LXXXI. Nomen-
clature and classification of adenosine receptors–an update. Pharmacol
Rev 63:1–34. CrossRef Medline
Fujioka M, Kanzaki S, Okano HJ, Masuda M, Ogawa K, Okano H (2006)
Proinflammatory cytokines expression in noise-induced damaged co-
chlea. J Neurosci Res 83:575–583. CrossRef Medline
Gunewardene N, Guo CX, Wong ACY, Thorne PR, Vlajkovic SM (2013)
Adenosine amine congener ameliorates cisplatin-induced hearing loss.
World Journal of Otorhinolaryngology 3:100–107. CrossRef
Hasko´ G, Szabo´ C, Ne´meth ZH, Kvetan V, Pastores SM, Vizi ES (1996)
Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and
nitric oxide production in RAW 264.7 macrophages and in endotoxemic
mice. J Immunol 157:4634–4640. Medline
Hight NG, McFadden SL, Henderson D, Burkard RF, Nicotera T (2003)
Noise-induced hearing loss in chinchillas pre-treated with glutathione
monoethylester and R-PIA. Hear Res 179:21–32. CrossRef Medline
Hu BH, Zheng XY, McFadden SL, Kopke RD, Henderson D (1997)
R-phenylisopropyladenosine attenuates noise-induced hearing loss in the
chinchilla. Hear Res 113:198–206. CrossRef Medline
JainN, Zhang T, Fong SL, LimCP, CaoX (1998) Repression of Stat3 activity
by activation of mitogen-activated protein kinase (MAPK). Oncogene
17:3157–3167. CrossRef Medline
Jain N, Zhang T, Kee WH, Li W, Cao X (1999) Protein kinase C delta asso-
ciates with and phosphorylates Stat3 in an interleukin-6-dependentman-
ner. J Biol Chem 274:24392–24400. CrossRef Medline
Jajoo S,Mukherjea D, Pingle S, Sekino Y, Ramkumar V (2006) Induction of
adenosine A1 receptor expression by pertussis toxin via an adenosine
5-diphosphate ribosylation-independent pathway. J Pharmacol Exp
Ther 317:1–10. Medline
Jajoo S, Mukherjea D, Watabe K, Ramkumar V (2009) Adenosine A(3) re-
ceptor suppresses prostate cancer metastasis by inhibiting NADPH oxi-
dase activity. Neoplasia 11:1132–1145. CrossRef Medline
Kaur T, Mukherjea D, Sheehan K, Jajoo S, Rybak LP, Ramkumar V (2011)
Short interfering RNA against STAT1 attenuates cisplatin-induced oto-
toxicity in the rat by suppressing inflammation. Cell Death Dis 2:e180.
CrossRef Medline
Kochanek PM, Vagni VA, Janesko KL, Washington CB, Crumrine PK, Gar-
man RH, Jenkins LW, Clark RS, Homanics GE, Dixon CE, Schnermann J,
Jackson EK (2006) AdenosineA1 receptor knockoutmice develop lethal
status epilepticus after experimental traumatic brain injury. J CerebBlood
Flow Metab 26:565–575. CrossRef Medline
Lankford AR, Yang JN, Rose’Meyer R, French BA, Matherne GP, Fredholm
BB, Yang Z (2006) Effect of modulating cardiac A1 adenosine receptor
expression on protection with ischemic preconditioning. Am J Physiol
Heart Circ Physiol 290:H1469–1473. Medline
Lee JS, Kang SU, HwangHS, Pyun JH, Choung YH, KimCH (2010) Epicat-
echin protects the auditory organ by attenuating cisplatin-induced oto-
toxicity through inhibition of ERK. Toxicol Lett 199:308–316. CrossRef
Medline
Liberman MC, Tartaglini E, Fleming JC, Neufeld EJ (2006) Deletion of
SLC19A2, the high affinity thiamine transporter causes selective inner
hair cell loss and an auditory neuropathy phenotype. JARO 7:211–217.
CrossRef Medline
Lim CP, Cao X (1999) Serine phosphorylation and negative regulation of
Stat3 by JNK. J Biol Chem 274:31055–31061. CrossRef Medline
May LA, Kramarenko II, Brandon CS, Voelkel-Johnson C, Roy S, Truong K,
Francis SP, Monzack EL, Lee FS, Cunningham LL (2013) Inner ear
supporting cells protect hair cells by secreting HSP70. J Clin Invest 123:
3577–3587. CrossRef Medline
Merchant SN, Gopen Q (1996) A human temporal bone study of acute
bacterial meningogenic labyrinthitis. Am J Otol 17:375–385. Medline
Mirza A, Basso A, Black S, Malkowski M, Kwee L, Pachter JA, Lachowicz JE,
Wang Y, Liu S (2005) RNA interference targeting of A1 receptor-
expressing breast carcinoma cells leads to diminished rates of cell prolif-
eration and induction of apoptosis. Cancer Bio Ther 4:1355–1360.
CrossRef
Mukherjea D, Jajoo S, Whitworth C, Bunch JR, Turner JG, Rybak LP, Ram-
kumar V (2008) Short interfering RNA against transient receptor po-
tential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat.
J Neurosci 28:13056–13065. CrossRef Medline
Mukherjea D, Jajoo S, Kaur T, Sheehan KE, Ramkumar V, Rybak LP (2010)
Transtympanic administration of short interfering (si)RNA for theNOX3
isoform of NADPH oxidase protects against cisplatin-induced hearing
loss in the rat. Antioxid Redox Signal 13:589–598. CrossRef Medline
Mukherjea D, Jajoo S, Sheehan K, Kaur T, Sheth S, Bunch J, Perro C, Rybak
LP, Ramkumar V (2011) NOX3 NADPH oxidase couples transient re-
ceptor potential vanilloid 1 to signal transducer and activator of transcrip-
tion 1-mediated inflammation and hearing loss. Antioxid Redox Signal
14:999–1010. CrossRef Medline
Nakai Y, Konishi K, Chang KC, Ohashi K,Morisaki N,Minowa Y,Morimoto
A (1982) Ototoxicity of the anticancer drug cisplatin: an experimental
study. Acta Oto-laryngologica 93:227–232. CrossRef Medline
Nario K, Kitano I, Mori N, Matsunaga T (1994) The effect of adenosine on
cochlear potentials in the guinea pig. Eur Arch Otorhinolaryngol 251:
428–433. Medline
Nie Z, Mei Y, Ford M, Rybak L, Marcuzzi A, Ren H, Stiles GL, Ramkumar V
(1998) Oxidative stress increases A1 adenosine receptor expression by
activating nuclear factor kappa B. Mol Pharmacol 53:663–669. Medline
Paparella MM, OdaM, Hiraide F, Brady D (1972) Pathology of sensorineu-
ral hearing loss in otitis media. Ann Otol Rhinol Laryngol 81:632–647.
CrossRef Medline
Pingle SC,Mishra S, Marcuzzi A, Bhat SG, Sekino Y, Rybak LP, Ramkumar V
(2004) Osmotic diuretics induce adenosine A1 receptor expression and
protect renal proximal tubular epithelial cells against cisplatin-mediated
apoptosis. J Biol Chem 279:43157–43167. CrossRef Medline
Pingle SC, Jajoo S, Mukherjea D, Sniderhan LF, Jhaveri KA, Marcuzzi A,
Rybak LP, Maggirwar SB, Ramkumar V (2007) Activation of the aden-
osine A1 receptor inhibits HIV-1 tat-induced apoptosis by reducing nu-
clear factor-kappaB activation and inducible nitric-oxide synthase. Mol
Pharmacol 72:856–867. CrossRef Medline
Previati M, Lanzoni I, Astolfi L, Fagioli F, Vecchiati G, Pagnoni A, Martini A,
Capitani S (2007) Cisplatin cytotoxicity in organ of Corti-derived im-
mortalized cells. J Cell Biochem 101:1185–1197. CrossRef Medline
Puntambekar P, Van Buren J, Raisinghani M, Premkumar LS, Ramkumar V
(2004) Direct interaction of adenosine with the TRPV1 channel protein.
J Neurosci 24:3663–3671. CrossRef Medline
Ramkumar V, Ravi R, Wilson MC, Gettys TW, Whitworth C, Rybak LP
(1994) Identification of A1 adenosine receptors in rat cochlea coupled to
inhibition of adenylyl cyclase. Am J Physiol 267:C731–737. Medline
Ribeiro L, Azevedo I, Martel F (2002) Comparison of the effect of cyclic
AMP on the content and release of dopamine and 1-methyl-4-
phenylpyridinium (Mpp) in PC12 cells. Auton Autacoid Pharmacol
22:277–289. CrossRef Medline
Rivolta MN, Grix N, Lawlor P, Ashmore JF, Jagger DJ, Holley MC (1998)
Auditory hair cell precursors immortalized from the mammalian ear.
Proc Biol Sci 265:1595–1603. CrossRef Medline
Rousset F, Carnesecchi S, Senn P, Krause KH (2015) NOX3 targeted thera-
pies for inner ear pathologies. Curr Pharm Des 21:5977–5987. CrossRef
Medline
Rudolphi KA, KeilM, Fastbom J, FredholmBB (1989) Ischaemic damage in
gerbil hippocampus is reduced following upregulation of adenosine (A1)
receptors by caffeine treatment. Neurosci Lett 103:275–280. CrossRef
Medline
Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB (1992) Adenosine
and brain ischemia. Cerebrovasc Brain Metab Rev 4:346–369. Medline
Rybak LP,Whitworth CA,Mukherjea D, Ramkumar V (2007) Mechanisms
of cisplatin-induced ototoxicity and prevention. Hear Res 226:157–167.
CrossRef Medline
Rybak LP, Mukherjea D, Jajoo S, Kaur T, Ramkumar V (2012) siRNA-
mediated knock-down of NOX3:therapy for hearing loss? Cell Mol Life
Sci 69:2429–2434. CrossRef Medline
Saito M, Yaguchi T, Yasuda Y, Nakano T, Nishizaki T (2010) Adenosine
3976 • J. Neurosci., April 6, 2016 • 36(14):3962–3977 Kaur, Borse et al. • A1AR and Cisplatin Ototoxicity
suppresses CW2 human colonic cancer growth by inducing apoptosis via
A(1) adenosine receptors. Cancer Lett 290:211–215. CrossRef Medline
Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS (1996)
Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine
receptors. J Immunol 156:3435–3442. Medline
Schmitt NC, Rubel EW, Nathanson NM (2009) Cisplatin-induced hair cell
death requires STAT1 and is attenuated by epigallocatechin gallate. JNeu-
rosci 29:3843–3851. CrossRef Medline
Schulte G, Sommerschild H, Yang J, Tokuno S, GoinyM, Lo¨vdahl C, Johansson
B, Fredholm BB, Valen G (2004) Adenosine A receptors are necessary for
protection of the murine heart by remote, delayed adaptation to ischaemia.
Acta Physiol Scand 182:133–143. CrossRefMedline
Simon AR, Rai U, Fanburg BL, Cochran BH (1998) Activation of the JAK-
STAT pathway by reactive oxygen species. Am J Physiol 275:C1640–
C1652. Medline
SoH,KimH, Lee JH, ParkC, KimY,KimE,Kim JK, YunKJ, LeeKM, LeeHY,
Moon SK, LimDJ, Park R (2007) Cisplatin cytotoxicity of auditory cells
requires secretions of proinflammatory cytokines via activation of ERK
and NF-kappaB. J Assoc Res Otolaryngol 8:338–355. CrossRef Medline
SoH, KimH,KimY, KimE, PaeHO, ChungHT, KimHJ, KwonKB, Lee KM,
Lee HY, Moon SK, Park R (2008) Evidence that cisplatin-induced audi-
tory damage is attenuated by downregulation of pro-inflammatory cyto-
kines via Nrf2/HO-1. J Assoc Res Otolaryngol 9:290–306. CrossRef
Medline
Soong R, Beyser K, Basten O, Kalbe A, Rueschoff J, Tabiti K (2001) Quan-
titative reverse transcription-polymerase chain reaction detection of cy-
tokeratin 20 in noncolorectal lymph nodes. Clin Cancer Res 7:3423–3429.
Medline
Stephanou A, Scarabelli TM, Brar BK, Nakanishi Y, Matsumura M, Knight
RA, Latchman DS (2001) Induction of apoptosis and Fas receptor/Fas
ligand expression by ischemia/reperfusion in cardiac myocytes requires
serine 727 of the STAT-1 transcription factor but not tyrosine 701. J Biol
Chem 276:28340–28347. CrossRef Medline
Tabuchi K, Nishimura B, Nakamagoe M, Hayashi K, Nakayama M, Hara A
(2011) Ototoxicity: mechanisms of cochlear impairment and its preven-
tion. Curr Med Chem 18:4866–4871. CrossRef Medline
Tsutsui S, Schnermann J, Noorbakhsh F, Henry S, Yong VW, Winston BW,
Warren K, Power C (2004) A1 adenosine receptor upregulation and ac-
tivation attenuates neuroinflammation and demyelination in a model of
multiple sclerosis. J Neurosci 24:1521–1529. CrossRef Medline
Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank
DA, Holzman LB, Wu J, Sebti S, Jove R (1999) Requirement for Ras/
Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3
transcriptional activity induced by the Src oncoprotein. Mol Cell Biol
19:7519–7528. CrossRef Medline
Vlajkovic SM, Abi S, Wang CJ, Housley GD, Thorne PR (2007) Differential
distribution of adenosine receptors in rat cochlea. Cell Tissue Res 328:
461–471. CrossRef Medline
Vlajkovic SM, Housley GD, Thorne PR (2009) Adenosine and the auditory
system. Curr Neuropharmacol 7:246–256. CrossRef Medline
Vlajkovic SM, Lee KH,WongAC,GuoCX,Gupta R,HousleyGD, Thorne PR
(2010) Adenosine amine congener mitigates noise-induced cochlear in-
jury. Purinergic Signal 6:273–281. CrossRef Medline
Vlajkovic SM, Guo CX, Telang R, Wong AC, Paramananthasivam V, Boison
D, Housley GD, Thorne PR (2011) Adenosine kinase inhibition in the
cochlea delays the onset of age-related hearing loss. Exp Gerontol 46:
905–914. CrossRef Medline
Von Lubitz DK, Lin RC, Melman N, Ji XD, Carter MF, Jacobson KA (1994)
Chronic administration of selective adenosine A1 receptor agonist or
antagonist in cerebral ischemia. Eur J Pharmacol 256:161–167. CrossRef
Medline
Wen Z, Zhong Z, Darnell JE Jr (1995) Maximal activation of transcription
by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell
82:241–250. CrossRef Medline
Whitworth CA, Ramkumar V, Jones B, Tsukasaki N, Rybak LP (2004) Pro-
tection against cisplatin ototoxicity by adenosine agonists. BiochemPhar-
macol 67:1801–1807. CrossRef Medline
Wu YJ, Muldoon LL, Neuwelt EA (2005) The chemoprotective agent
N-acetylcysteine blocks cisplatin-induced apoptosis through caspase sig-
naling pathway. J Pharmacol Exp Ther 312:424–431. Medline
Zauberman A, Zipori D, Krupsky M, Ben-Levy R (1999) Stress activated
protein kinase p38 is involved in IL-6 induced transcriptional activation
of STAT3. Oncogene 18:3886–3893. CrossRef Medline
ZhangX, Blenis J, Li HC, Schindler C, Chen-Kiang S (1995) Requirement of
serine phosphorylation for formation of STAT-promoter complexes. Sci-
ence 267:1990–1994. CrossRef Medline
Kaur, Borse et al. • A1AR and Cisplatin Ototoxicity J. Neurosci., April 6, 2016 • 36(14):3962–3977 • 3977
